REGENERON
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcuta... neous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.
REGENERON
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1988-01-01
Address:
Tarrytown, New York, United States
Country:
United States
Website Url:
http://www.regeneron.com
Total Employee:
5001+
Status:
Active
Contact:
+118557343648
Total Funding:
8.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Content Delivery Network Domain Not Resolving
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-04-19 | Checkmate Pharmaceuticals | Checkmate Pharmaceuticals acquired by Regeneron | 250 M USD |
Investors List
U.S. Department of Health & Human Services
U.S. Department of Health & Human Services investment in Post-IPO Equity - Regeneron
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-05-17 | Vyriad | Regeneron investment in Series B - Vyriad | 29.5 M USD |
| 2020-06-09 | DNAnexus | Regeneron investment in Series G - DNAnexus | 100 M USD |
| 2019-09-02 | Adicet Bio | Regeneron investment in Series B - Adicet Bio | 80 M USD |
| 2019-04-08 | Alnylam Pharmaceuticals | Regeneron investment in Post-IPO Equity - Alnylam Pharmaceuticals | 800 M USD |
| 2018-06-19 | Decibel Therapeutics | Regeneron investment in Series C - Decibel Therapeutics | 55 M USD |
Newest Events participated
Official Site Inspections
http://www.regeneron.com Semrush global rank: 341.1 K Semrush visits lastest month: 176.15 K
- Host name: 192.103.124.65
- IP address: 192.103.124.65
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Regeneron"
Regeneron’s Leadership Team - Regeneron Pharmaceuticals
Marion McCourt joined Regeneron in 2018 and serves as executive vice president and head of the commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a …See details»
About Regeneron | Our Company
About Regeneron. Our mission is to use the power of science to bring new medicines to patients ... over and over again. We are a leading biotechnology company that invents, develops and …See details»
Corporate Governance Committee | Regeneron Investors
Explore Regeneron's Board of Directors committee composition, including members or chairpersons on each committee.See details»
Corporate Governance | Regeneron Investors
The Board of Directors of Regeneron Pharmaceuticals, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the …See details»
Regeneron Pharmaceuticals - Wikipedia
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [ 2 ] Originally focused on neurotrophic factors and their regenerative …See details»
Regeneron's 2025 Responsibility Goals
“Regeneron was founded on the philosophy of ‘Doing Well by Doing Good’ because our founders believed it was crucial to achieving our mission of improving people’s lives. This ethos permeates throughout our company – …See details»
Annual Reports & Proxy Statements | Regeneron Investors
Download Regeneron's Annual Reports, Proxy Statements, and Environmental, Social and Governance Reports.See details»
Regeneron Canada: Push the Bounds of Science
Regeneron-invented medicines are available in over 100 countries and are being studied in clinical trials in approximately 60 countries. Our unique ability to repeatedly and consistently translate science into medicine has led to …See details»
REGN Corporate Presentation - investor.regeneron.com
Oct 31, 2024 Regeneron's research programs; the likelihood and timing of achieving any of the anticipated milestones discussed or referenced in this presentation; safety issues resulting …See details»
Canada - Regeneron Careers
Regeneron is a global biotechnology company that invents life-transforming medicines for people with serious diseases. Founded in 1988, Regeneron is still run by physician-scientists Len Schleifer, MD, PhD and George Yancopoulos, …See details»
Inclusion & Culture | Regeneron
At Regeneron, we are driven by a strong sense of purpose. Fostering diversity and inclusion is core to our mission, our culture and our commitment to patients. Our approach provides a …See details»
Press Releases | Regeneron Investors
Dec 8, 2024 Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH. Read press release. November …See details»
Regeneron 2022 Year in Review | Life-changing Medicines
Using the power of science to repeatedly bring new medicines to patients is what we do at Regeneron. In 2022, we continued to reinforce our leadership in retinal disease with ongoing …See details»
Financial Information | Regeneron Investors
Feb 5, 2024 Find Regeneron's financial information and download important documents and U.S. Securities and Exchange Commission filings like the Annual Report, Proxy Statement, 10 …See details»
Regeneron Corporate Presentation
Regeneron’sand its collaborators’earlier-stage programs, and the use of human genetics in Regeneron’sresearch programs; safety issues resulting from the administration of …See details»
Regeneron - Leadership Team - The Org
The Leadership Team at Regeneron Pharmaceuticals is responsible for guiding the strategic direction and operational execution of the company. Comprising senior executives from …See details»
Regeneron's History | Over 35 Years of Scientific Innovation
Regeneron and Intellia announce first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing. Regeneron Genetics Center discovers GPR75 gene mutations …See details»
Upcoming & Recent Events | Regeneron Investors
Oct 31, 2024 Explore Regeneron's upcoming and recent events, including webcasts, transcripts, presentations of recent events, and details about upcoming events.See details»
Regeneron's CEO and Executive Team - Team members and org …
The executive team at Regeneron has a history of working in various industries including health and life sciences, Accenture, and Dow Chemical. They have a range of education levels, from …See details»
Media Statements | Regeneron Investors
Apr 15, 2024 You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read …See details»